Cox 2 Inhibitor News and Research

RSS

Cox-2 Inhibitors are nonsteroidal anti-inflammatory drugs used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. Also called cyclo-oxygenase-2 inhibitor.

New drug combo emerges as a potential candidate for oral pericoital contraception

A new combination of drugs has emerged as a "promising candidate" for an on-demand contraceptive pill, suggests preliminary research published online in the journal BMJ Sexual & Reproductive Health.

26 Apr 2022

Researchers identify new treatment for osteoarthritis

The study results revolve around the long-established idea that machines within animal and human cells turn the sugars, fats, and proteins we eat into energy used by the body's millions of cells.

10 Aug 2020

New drug combination successfully reduces levels of bovine leukemia virus

Scientists have succeeded in reducing levels of the bovine leukemia virus in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

2 Aug 2019

New anti-inflammatory compound acts as 'surge protector' to reduce cancer growth

A new anti-inflammatory compound developed at the University of California, Davis, acts as a "surge protector" to suppress inflammation and reduce cancer growth, at least in mouse models of cancer.

17 Jan 2019

UH pharmaceutical scientist developing new drug to treat children with rare genetic disorder

A University of Houston pharmaceutical scientist is developing a new drug which could bring relief to children suffering with Familial Adenomatous Polyposis, a rare genetic disorder characterized by hundreds - if not thousands - of colorectal polyps.

21 Nov 2018

Researchers unravel immunopathogenesis of Johne's disease

A research team has unraveled the immunopathogenesis of Johne's disease, a chronic bovine disease that has caused endemics in Japan and many other countries, placing financial burdens on cattle farmers.

2 Apr 2018

NSAIDs may not be safe for arthritis patients with cardiovascular risk, study shows

Ibuprofen is associated with increased blood pressure and hypertension compared to celecoxib in patients with osteoarthritis or rheumatoid arthritis and increased risk of cardiovascular disease, according to late-breaking results from the PRECISION-ABPM study presented today in a Hot Line Session at ESC Congress and published in EHJ.

28 Aug 2017

Study suggests revolutionary way to make cancer cells more susceptible to existing chemotherapies

The same signal that drives aggressive growth in a deadly cancer cell type also triggers coping mechanisms that make it "notoriously" hard to kill, according to a study published online December 15 in Cell. When stressed, this cell type - far more than most cancer cells - encases its genetic messages in protein globs called "stress granules" that lessen the effect of chemotherapies.

16 Dec 2016

UA study questions safety and efficacy of selenium in reducing risk of colorectal cancer

A 12-year study led by a team of University of Arizona Cancer Center researchers is bringing into question the safety and efficacy of selenium, a popular nutritional supplement touted to combat and reduce the risk of colorectal cancer.

14 Oct 2016

LSU Health New Orleans finalizes deal with CB BioSciences

The Office of Technology Management at LSU Health New Orleans has finalized a deal with CB BioSciences, Inc., a startup drug development company to build a platform around the intellectual property portfolio of Chu Chen, PhD, LSU Health New Orleans Professor of Neuroscience.

23 Feb 2015

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

18 Nov 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.

14 Jul 2014

Effective strategy for noninvasive detection of cancer

Molecules that bind and illuminate proteins specific to tumor cells are key to detecting cancer as early as possible. The cyclooxygenase-2 enzyme is just such a protein, as the concentration of COX-2 is greater in cancer cells than in adjacent normal tissues.

5 Nov 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

COX-2 inhibitor extends sunitinib activity in renal cell carcinoma

The effectiveness of sunitinib for the treatment of renal cell carcinoma could be enhanced with the addition of a cyclooxygenase-2 inhibitor, study findings show.

20 Feb 2013

Positive results from CrystalGenomics’ CG100649 Phase 2b OA study

CrystalGenomics, Inc., a biopharmaceutical company headquartered in Korea, has just announced positive results from the Phase 2b osteoarthritis (OA) study of the CG100649, CrystalGenomics' next-generation NSAID candidate.

19 Apr 2012

Decreasing GPA adherence among COX-2 users increases risk of upper GI complications

To relieve pain, arthritis sufferers are prescribed medications that may include non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors, both of which can irritate the digestive tract. At times additional drugs are co-prescribed with NSAIDs or COX-2 inhibitors to prevent adverse gastrointestinal (GI) effects.

16 Apr 2012

Aspirin may benefit HIV-infected women at risk of cervical cancer

Research conducted by NewYork-Presbyterian Hospital/Weill Cornell Medical Center global health investigators and cancer specialists in New York, Qatar and Haiti suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV-infected women.

19 Jan 2012

NSAIDs like ibuprofen slow the spread of breast cancers

Published online on Aug. 7, 2011, the journal Nature Medicine reports that non-steroidal anti-inflammatory drugs including ibuprofen reduce the severity of postpartum breast cancers in animal models.

12 Aug 2011